Wave Life Sciences Ltd
$ 14.54
3.71%
25 Feb - close price
- Market Cap 2,700,949,000 USD
- Current Price $ 14.54
- High / Low $ 14.57 / 14.00
- Stock P/E N/A
- Book Value 0.78
- EPS -0.65
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.86 %
- 52 Week High 21.73
- 52 Week Low 5.28
About
Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes and produces new stereopure oligonucleotides through PRISM, a drug discovery and development platform. The company is headquartered in Singapore.
Analyst Target Price
$33.38
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-07-30 | 2025-05-07 | 2025-03-04 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-06 | 2023-11-09 | 2023-08-03 | 2023-05-03 | 2023-03-22 |
| Reported EPS | -0.32 | -0.31 | -0.29 | 0.17 | -0.466 | -0.25 | -0.24 | -0.15 | 0.07 | -0.2 | -0.27 | -0.47 |
| Estimated EPS | -0.2547 | -0.27 | -0.2556 | -0.17 | -0.28 | -0.21 | -0.21 | -0.23 | -0.18 | -0.33 | -0.04 | -0.41 |
| Surprise | -0.0653 | -0.04 | -0.0344 | 0.34 | -0.186 | -0.04 | -0.03 | 0.08 | 0.25 | 0.13 | -0.23 | -0.06 |
| Surprise Percentage | -25.638% | -14.8148% | -13.4585% | 200% | -66.4286% | -19.0476% | -14.2857% | 34.7826% | 138.8889% | 39.3939% | -575% | -14.6341% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: WVE
2026-02-25 15:53:15
Wave Life Sciences Ltd is set to report its fourth-quarter earnings, with analysts anticipating a loss of 27 cents per share on revenues of $17.2 million. Investors are keenly focused on the company's dual strategy in obesity and rare diseases, particularly its obesity candidate WVE-007, which has shown promising fat loss results. Despite previous earnings misses, all 16 analysts rate the stock a Strong Buy, signaling strong confidence in Wave's clinical pipeline and strategic shifts, including regaining full rights to WVE-006 for alpha-1 antitrypsin deficiency.
2026-02-24 05:53:12
Wave Life Sciences has gained investor interest after reacquiring rights to its RNA editing candidate WVE-006 and renewed focus on its obesity program WVE-007. Despite recent strong stock performance (80.83% in 90 days), the company's valuation narrative suggests it is 59.6% undervalued with a fair value of $33.38, significantly above its current $13.49. However, concerns remain regarding weak recent collaboration revenue, widening losses, and a high Price to Sales ratio compared to industry averages and fair value.
2026-02-23 14:03:21
Wave Life Sciences Ltd. announced that its President and CEO, Paul Bolno, MD, MBA, will participate in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. A live webcast of the presentation will be available on the company's investor relations website, with a replay archived for a limited time. Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines for rare and common disorders.
2026-02-23 13:53:12
Wave Life Sciences will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Paul Bolno, MD, MBA, President and CEO, is scheduled to engage in an analyst-led fireside chat on Thursday, February 26, 2026, at 2:40 p.m. ET. A live webcast and archived replay will be available on the company's investor relations website.
2026-02-23 13:44:14
Wave Life Sciences (Nasdaq: WVE) announced that its President and CEO, Paul Bolno, MD, MBA, will participate in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference. The event is scheduled for Thursday, February 26, 2026, at 2:40 p.m. ET. A live webcast and subsequent replay will be available on the company's investor relations website.
2026-02-20 06:55:25
WAVE Life Sciences (WVE) stock saw a rise following analyst attention and news regarding its drug pipeline. BofA highlighted WVE-007 as a primary growth driver, projecting peak sales over $11 billion, and the company regained full rights to its WVE-006 Alpha-1 Antitrypsin Deficiency therapy, aiming for accelerated regulatory engagement. Investors are also anticipating the company's Q4 and full-year 2025 financial results.
